WebMethods: The AFIRE trial (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) was a multicenter, open-label trial conducted in Japan. WebDec 3, 2024 · Randomization to twice daily apixaban 2.5 mg, apixaban 5 mg, or placebo with stratification by DVT/PE and participation in AMPLIFY trial within ~7 days of completion of AC; For those on warfarin, therapy was not started until the INR was ≤2; Outcomes. Results presented as apixaban 2.5 mg vs. apixaban 5 mg vs. placebo.
Glossary – NERDCAT - BCcampus
WebFeb 22, 2024 · AFIRE - Antithrombotics for AF + stable CAD — NERDCAT Making evidence appraisal easy for clinicians AFIRE - Antithrombotics for AF + stable CAD February 22, … Non-inferiority trial. Non-inferiority margin set as a 2% absolute risk increase for … Pharmacists' scope of practice is rapidly evolving to include more sophisticated … EAST-AFNET 4 trial: Is a rhythm control strategy superior to rate control in … The approved “full dose” of rivaroxaban for stroke prophylaxis in AF in Japan is 15 … AFIRE - Antithrombotics for AF + stable CAD. February 22, 2024 by Ricky … The NERDCAT program started in 2012 as a pharmacy resident journal club and … WebMar 25, 2024 · Patients with heart arrythmia (atrial fibrillation) have a high risk for thrombotic events in blood vessels that could lead to permanent organ damage -- such as cerebral infarction -- and are... free download tera term software
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and ...
WebMar 18, 2024 · NEW ORLEANS, LA—Two new trials indicate that short-term dual antiplatelet therapy (DAPT) followed by P2Y12-inhibitor monotherapy may provide more of a benefit than 12 months of DAPT among certain PCI patients receiving current-generation DES. WebSep 3, 2024 · The AFIRE trial (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) demonstrated that compared with combination therapy with rivaroxaban (a non–vitamin K antagonist oral anticoagulant) plus a single antiplatelet agent, rivaroxaban monotherapy was noninferior in terms of … WebOct 18, 2024 · In the AFIRE trial, 47.5% of patients had histories of myocardial infarction, stroke, or peripheral artery disease. For the purpose of this study, these participants constituted the atherothrombosis group, while the remaining constituted the non‐atherothrombosis group. bloom rocket league song